Medtronic Finally Looks Alive Again

Medtronic is not usually the stock investors turn to for adrenaline, but its latest quarter gave Wall Street a much healthier readout. The medical-device giant reported fourth-quarter revenue of $9.8 billion, up 9.9% from a year earlier and 6.6% on an organic basis, while adjusted earnings came in at $1.55 per share. Shares rose about 5% Wednesday after the results, as investors found something that has not always been easy to spot in large-cap medtech — growth that finally had a pulse.

The strongest signal came from the heart business. Medtronic’s Cardiovascular portfolio generated $3.8 billion in revenue, up 13.8% as reported and 10.1% organically, while Cardiac Ablation Solutions revenue jumped 78% globally and 124% in the U.S. That matters because pulsed field ablation has turned into one of the more important growth lanes in heart treatment, giving Medtronic a solid answer for investors who have wanted faster expansion from a company often valued more for durability than speed.

Medtronic also gave investors a bigger future-growth hook outside the current numbers. The company filed a submission with U.S. regulators to expand its Hugo robotic-assisted surgery system into general surgery and gynecologic procedures, a move that would push it deeper into one of the most closely watched areas in medical technology. Surgical robotics is not a small side bet. It is a chance for Medtronic to compete in a market where hospitals are already spending heavily and procedures are becoming more technology-driven. For a company trying to look more alive, a deeper push into surgical robotics gives investors another reason to keep the chart open.

The outlook was not perfect, but for Medtronic, steady growth with improving momentum was enough. The company guided for fiscal 2027 organic revenue growth of 6.75% to 7.25% and adjusted earnings of $5.90 to $6.00 per share, while also raising its quarterly dividend to $0.72 per share for its 49th consecutive annual increase. That leaves Medtronic in an unusually useful position for investors — still defensive, still cash-generative, but suddenly growing in more interesting ways. After this quarter, Medtronic was not suddenly cured of every investor concern. It emerged as something more useful — a mature medtech name with stronger vitals than Wall Street had been giving it credit for.

Disclaimer: This content is for informational and entertainment purposes only and does not constitute financial or investment advice. The information provided may be outdated or contain inaccuracies. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Investing involves risk, including the potential loss of principal. Unless explicitly stated otherwise, neither Equiscreen, LLC nor its beneficial owners hold any financial interest in the companies mentioned in our articles, and we do not receive compensation for including them. Equiscreen, LLC and its beneficial owners may buy or sell securities of any company referenced in our content at any time and without prior notice, and nothing published by Equiscreen, LLC should be interpreted as a recommendation to buy, sell, or hold any security. Any paid content or income-related materials will be clearly identified as “Sponsored” or “Advertorial,” and corresponding income disclosures can be found at the bottom of the page. For additional information, please contact [email protected].

Top Gainers

Top Losers

U.S. Commodities

2234 N Federal Hwy # 1022
Boca Raton, FL 33431

(561) 264-5726